机构：[1]Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.临床科室变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.首都医科大学附属北京同仁医院研究所耳鼻咽喉科研究所[3]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a common and challenging clinical entity, and its economic burden has not been well described in China thus far.A total of 101 CRSwNP patients who underwent endoscopic sinus surgery were included to investigate direct costs in the first year post-surgery. Costs for outpatient visits, medication use, and examination costs were obtained from the Hospital Information System, and differences were compared between subgroups. Multiple linear regression analysis was adopted to investigate the main influencing factors on annual total direct costs for CRSwNP patients.Ninety-two subjects completed the study. The individual mean total direct cost for a CRSwNP patient 1 year post-surgery was $742.4. The largest contributors were pharmacy costs ($580.2), followed by examination costs ($108.1) and outpatient visits ($54.1). Total direct costs were higher in subgroups of patients with uncontrolled clinical status, asthma comorbidity, and eosinophilic CRSwNP compared to their counterparts. The main influencing factors were clinical control status (P = 0.016) and asthma comorbidity (P = 0.035).The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.
基金：
This work was supported by grants from national key R&D program of
China (2022YFC2504100), the program for the Changjiang scholars and
innovative research team (IRT13082), CAMS innovation fund for medical
sciences (2019-I2M-5-022), Capital’s funds for health improvement and
research (2022-1-1091), Natural Science Foundation of China (81970849,
82071022 and 82271141) and Beijing Municipal Science & Technology
Commission (Z211100002921060).
第一作者机构：[1]Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.[2]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.[3]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.[4]Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.[*1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University,Beijing 100730, China[*2]Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
推荐引用方式(GB/T 7714)：
Li Xian,Li Jingyun,Xu Xu,et al.Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps[J].EXPERT REVIEW OF CLINICAL IMMUNOLOGY.2023,19(11):1419-1425.doi:10.1080/1744666X.2023.2246660.
APA：
Li Xian,Li Jingyun,Xu Xu,She Wenyu,Wang Chengshuo...&Zhang Luo.(2023).Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps.EXPERT REVIEW OF CLINICAL IMMUNOLOGY,19,(11)
MLA：
Li Xian,et al."Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps".EXPERT REVIEW OF CLINICAL IMMUNOLOGY 19..11(2023):1419-1425
：